SCHEMBL643581

SCHEMBL643581

O=S(=O)(c1ccc(F)cc1)C1CCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.49
HTR2C P28335 5/20 0.49
KCNH2 Q12809 5/20 0.49
MMP8 P22894 4/20 0.45
MMP13 P45452 4/20 0.45
MMP1 P03956 3/20 0.45
TRPA1 O75762 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
CXCR2 P25025 1/20 0.43
DRD2 P14416 3/20 0.42
PTGS2 P35354 3/20 0.41
MMP2 P08253 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MMP9 P14780 1/20 0.41
PTGS1 P23219 2/20 0.41
EPHX2 P34913 1/20 0.40
MAPT P10636 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3240288 0.96 HTR2A (0.49) HTR2AHTR2CKCNH2MMP8MMP13
SCHEMBL644453 0.91 HTR2A (0.51) HTR2AHTR2CKCNH2MMP8MMP13
Formic Acid SCHEMBL28110710 0.91 HTR2A (0.44) HTR2AHTR2CKCNH2MMP8MMP13
SCHEMBL28057775 0.82 HTR2A (0.46) HTR2AHTR2CKCNH2MMP8MMP13
SCHEMBL5212828 0.82 CYP11B1 (0.49) HTR2AHTR2CKCNH2DRD2PTGS2
SCHEMBL28343860 0.82 HTR2A (0.46) HTR2AHTR2CKCNH2MMP8MMP13
Hydrochloric Acid SCHEMBL4095644 0.81 CYP11B1 (0.48) HTR2AHTR2CKCNH2DRD2PTGS2
SCHEMBL10799201 0.81 APLNR (0.47) HTR2AHTR2CKCNH2TRPA1CXCR2
SCHEMBL13209320 0.80 TRPA1 (0.41) HTR2AHTR2CMMP8MMP13MMP1
Hydrochloric Acid SCHEMBL10800269 0.79 APLNR (0.46) HTR2AHTR2CKCNH2TRPA1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720065-A1 PRMT5 INHIBITORS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-04-08 EP disclosed
WO-2024245412-A1 PRMT5 INHIBITORS AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2024-12-05 WO disclosed
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-8119624-B2 Fused phenyl amido heterocyclic compounds PFIZER INC. (US) 2012-02-21 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds PFIZER INC 2011-02-17 US disclosed
EP-1992623-A1 Heteroaryl benzamide derivative for use as GLK activator in the treatment of diabetes Astra Zeneca AB (SE) 2008-11-19 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 US disclosed
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-17 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed
EP-1756076-A1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES AstraZeneca AB (SE) 2007-02-28 EP disclosed
WO-2005121110-A1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015203-A1 Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes GRK4, GRK5, GRK2 HTR2A 630/4885HTR2C 265/4885KCNH2 1439/4885
US-20110039821-A1 Fused Phenyl Amido Heterocyclic Compounds GCK, GCKR, HK1 HTR2A 1886/4885HTR2C 1872/4885KCNH2 307/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 HTR2A 1886/4885HTR2C 1872/4885KCNH2 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.